个人简历

【教育背景】 1997-2002年 南华大学，获学士学位 2004-2007年 南华大学，获硕士学位 2008-2011年 中南大学，获博士学位 2012-2014年 中山大学，博士后研究 2015-2017年 香港大学，香江学者

研究领域

长期致力于非编码RNA与肿瘤发生发展的分子机制，乳腺癌干细胞的起源与调控及活体成像转基因动物模型等方面的研究。

近期论文

1.Tang H ( #), Liu P, Yang L, Xie X, Ye F, Wu M, Liu X, Chen B, Zhang L, Xie X. miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer. Mol Cancer Ther. 2014 Dec;13(12):3185-97. 2.Tang H ( #), Deng M, Tang Y, Xie X, Guo J, Kong Y, Ye F, Su Q, Xie X. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression.Clin Cancer Res. 2013; 19(20):5602-5612. 3.Tang H ( #), Liu Q, Liu X, Ye F, Xie X, Xie X, Wu M. Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma. J Cancer Res Ther. 2015 Jul-Sep;11(3):630-4. 4.Tang H ( #), Kong Y, Guo J, Tang Y, Xie X, Yang L, Su Q, Xie X. Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Lett. 2013; 340(1):72-81. 5.Tang H ( #), Bian Y, Tu C, Wang Z, Yu Z, Liu Q, Xu G, Wu M, Li G. The miR-183/96/182 cluster centralizes to regulate oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. Curr Cancer Drug Targets. 2013; 13(2):221-31. 6.Tang H ( #), Wang Z, Liu X, Liu Q, Xu G, Li G, Wu M. LRRC4 inhibits glioma cells growth and invasion by miR-185 mediating pathway. Curr Cancer Drug Targets. 2012; 12(8):1032-42. 7.Tang H ( #), Wang Z, Liu Q, Liu X, Wu M, Guiyuan Li. Disturbing miR-182 and -381 Inhibits BRD7 Transcription and Glioma Growth by Directly Targeting LRRC4. PLoS ONE. 2014; 9(1): e84146. 8.Tang H ( #), Xie X, Guo J, Wei W, Wu M, Liu P, Kong Y, Yang L, Hung MC, Xie X. Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle. J Nanopart Res. 2014; 16:2213. 9.Tang H ( #), Liu X, Wang Z, She X, Zeng X, Deng M, Liao Q, Guo X, Wang R, Li X, Zeng F, Wu M, Li G. Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res. 2011; 1390:21-32. 10.Yang L, Tang H ( #), Kong Y, Xie X, Chen J, Song C, Liu X, Ye F, Li N, Wang N, Xie X. LGR5 Promotes Breast Cancer Progression And Maintains Stem-like Cells Through Activation Of Wnt/β-Catenin Signaling. Stem Cells. 2015 Oct;33(10):2913-24. 11.Liu X ( #), Tang H ( #), Chen J, Song C, Yang L, Liu P, Wang N, Xie X, Lin X, Xie X. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget. 2015 Aug 21;6(24):20070-83. 12.Xie X, Tang H ( #), Liu P, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT, Xie X. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 2015 Jan 28; 356(2 Pt B):374-81. 13.Chen B ( #), Tang H ( #), Liu X, Liu P, Yang L, Xie X, Ye F, Song C, Xie X, Wei W. miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Lett. 2015 Jan 28; 356(2 Pt B):410-7. 14.Liu P ( #), Tang H ( #), Chen B, He Z, Deng M, Wu M, Liu X, Yang L, Ye F, Xie X. miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett. 2015 Feb 1;357(1):384-92. 15.Ye F ( #), Tang H ( #), Liu Q, Xie X, Wu M, Liu X, Chen B, Xie X. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. J Transl Med. 2014;12(1):17. 16.Liu Q ( #), Tang H ( #),Liu X, Liao Y, Li H, Zhao Z, Yuan X, Jiang W. miR-200b as a prognostic factor targets multiple members of RAB family in glioma. Med Oncol. 2014;31(3):859.